Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in
- This topic has 0 replies, 1 voice, and was last updated 5 years, 3 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).
http://abstracts.asco.org/239/AbstView_239_252251.html
Viewing 1 post (of 1 total)
- The forum ‘Chemotherapy & More’ is closed to new topics and replies.